A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009367/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine if the addition of daratumumab to velcade
(bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared
with VMP alone in participants with previously untreated multiple myeloma who are ineligible
for high dose chemotherapy and autologous stem cell transplant (ASCT).
提供机构：
Vivli
创建时间：
2023-10-17
